Argenica Therapeutics' Neuroprotective Drug ARG-007 Shows Positive Results in Ferret Preclinical Study

MT NewswiresMay 14 18:54 ET

Argenica Therapeutics Price Target Cut 6.7% to A$1.40/Share by Euroz Hartleys

Dow JonesApr 15 21:51 ET

Argenica Therapeutics Doses First Batch of Patients for Phase Two Stroke Trial

MT NewswiresApr 9 22:14 ET

Argenica Therapeutics Doses First Patient in Phase Two Stroke Trial; Shares Rally 14%

MT NewswiresMar 27 20:30 ET

FDA Grants Argenica Rare Pediatric Disease Designation for Hypoxic Ischaemic Encephalopathy Treatment; Shares Up 16%

MT NewswiresMar 24 20:48 ET

Argenica Therapeutics Concludes Manufacturing, Release Testing for Stroke Drug; Shares Rise 3%

MT NewswiresFeb 11 22:52 ET